Overall survival and quality of life with [ 177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary out... by Emmett, Louise, Prof, Subramaniam, Shalini, MBBS, Crumbaker, Megan, PhD, Joshua, Anthony M, Prof, Sandhu, Shahneen, Prof, Nguyen, Andrew, MBBS, Weickhardt, Andrew, PhD, Lee, Sze-Ting, Prof, Ng, Siobhan, MBBS, Francis, Roslyn J, PhD, Goh, Jeffrey C, Prof, Pattison, David A, MBBS, Tan, Thean Hsiang, MBBS, Kirkwood, Ian D, MBBS, Gedye, Craig, PhD, Rutherford, Natalie K, MD, Kumar, Aravind S Ravi, MBBS, Pook, David, MD, Ramdave, Shakher, MD, Nadebaum, David P, MBBS, Voskoboynik, Mark, MBBS, Redfern, Andrew D, MBChB, Macdonald, William, MPH, Krieger, Laurence, MBChB, Schembri, Geoff, MBChB, Chua, Wei, PhD, Lin, Peter, MBBS, Horvath, Lisa, Prof, Bastick, Patricia, MBBS, Butler, Patrick, MD, Zhang, Alison Yan, PhD, McJannett, Margaret, RN, Thomas, Hayley, MBiostat, Langford, Ailsa, BSc, Hofman, Michael S, Prof, Martin, Andrew James, Prof, Davis, Ian D, Prof, Stockler, Martin R, Prof

Get full text

[ 177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial by Emmett, Louise, Prof, Subramaniam, Shalini, MBBS, Crumbaker, Megan, PhD, Nguyen, Andrew, MBBS, Joshua, Anthony M, Prof, Weickhardt, Andrew, PhD, Lee, Sze-Ting, Prof, Ng, Siobhan, MBBS, Francis, Roslyn J, PhD, Goh, Jeffrey C, Prof, Pattison, David A, MBBS, Tan, Thean Hsiang, MBBS, Kirkwood, Ian D, MBBS, Gedye, Craig, PhD, Rutherford, Natalie K, MD, Sandhu, Shahneen, MBBS, Kumar, Aravind Ravi, MBBS, Pook, David, MD, Ramdave, Shakher, MD, Nadebaum, David P, MBBS, Voskoboynik, Mark, MBBS, Redfern, Andrew D, MBChB, Macdonald, William, MPH, Krieger, Laurence, MBChB, Schembri, Geoff, MBChB, Chua, Wei, Prof, Lin, Peter, MBBS, Horvath, Lisa, Prof, Bastick, Patricia, MBBS, Butler, Patrick, MD, Zhang, Alison Yan, PhD, Yip, Sonia, PhD, Thomas, Hayley, MBiostat, Langford, Ailsa, BSc, Hofman, Michael S, Prof, McJannett, Margaret, RN, Martin, Andrew James, Prof, Stockler, Martin R, Prof, Davis, Ian D, Prof

Get full text

Overall survival with [ 177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 tr... by Hofman, Michael S, Prof, Emmett, Louise, Prof, Sandhu, Shahneen, MBBS, Iravani, Amir, MD, Buteau, James P, MD, Joshua, Anthony M, Prof, Goh, Jeffrey C, Prof, Pattison, David A, MBBS, Tan, Thean Hsiang, MBBS, Kirkwood, Ian D, MBBS, Ng, Siobhan, MBBS, Francis, Roslyn J, PhD, Gedye, Craig, PhD, Rutherford, Natalie K, MD, Weickhardt, Andrew, PhD, Scott, Andrew M, Prof, Lee, Sze-Ting, PhD, Kwan, Edmond M, PhD, Azad, Arun A, PhD, Ramdave, Shakher, MD, Redfern, Andrew D, MBChB, Macdonald, William, MPH, Guminski, Alex, PhD, Hsiao, Edward, MBChB, Chua, Wei, PhD, Lin, Peter, MBBS, Zhang, Alison Yan, PhD, Stockler, Martin R, Prof, Williams, Scott G, Prof, Martin, Andrew J, Prof, Davis, Ian D, Prof

Get full text

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [ 177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a bi... by Buteau, James P, MD, Martin, Andrew J, PhD, Emmett, Louise, Prof, Iravani, Amir, MD, Sandhu, Shahneen, MBBS, Joshua, Anthony M, Prof, Francis, Roslyn J, PhD, Zhang, Alison Y, PhD, Scott, Andrew M, Prof, Lee, Sze-Ting, PhD, Azad, Arun A, PhD, McJannett, Margaret M, Stockler, Martin R, Prof, Williams, Scott G, Prof, Davis, Ian D, Prof, Hofman, Michael S, Prof

Get full text